Phase 2b Bimekizumab study results in PsA shows neutralizing IL 17F and IL 17A may be a new target for LDA/treatment. https://t.co/45Vahy36g7 #ACR19 @uptoTate
abs#2881
Links:
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Acti…
http://bit.ly/2R2P0Ej
Nov-29-2019
